Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Inventory (2017 - 2023)

Historic Inventory for Avalo Therapeutics (AVTX) over the last 7 years, with Q2 2023 value amounting to $18000.0.

  • Avalo Therapeutics' Inventory fell 2173.91% to $18000.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $18000.0, marking a year-over-year decrease of 2173.91%. This contributed to the annual value of $20000.0 for FY2022, which is 4736.84% down from last year.
  • Per Avalo Therapeutics' latest filing, its Inventory stood at $18000.0 for Q2 2023, which was down 2173.91% from $19000.0 recorded in Q1 2023.
  • Over the past 5 years, Avalo Therapeutics' Inventory peaked at $1.0 million during Q1 2019, and registered a low of $3000.0 during Q4 2020.
  • For the 5-year period, Avalo Therapeutics' Inventory averaged around $107007.2, with its median value being $20000.0 (2021).
  • Per our database at Business Quant, Avalo Therapeutics' Inventory tumbled by 9844.54% in 2020 and then soared by 116666.67% in 2021.
  • Quarter analysis of 5 years shows Avalo Therapeutics' Inventory stood at $21334.0 in 2019, then crashed by 85.94% to $3000.0 in 2020, then skyrocketed by 1166.67% to $38000.0 in 2021, then tumbled by 47.37% to $20000.0 in 2022, then dropped by 10.0% to $18000.0 in 2023.
  • Its Inventory stands at $18000.0 for Q2 2023, versus $19000.0 for Q1 2023 and $20000.0 for Q4 2022.